Isolation of high-purity, label-free, and viable circulating tumour cells (CTCs) from cancer patients is crucial for subsequent analyses. To address this issue, a two-step CTC isolation scheme was proposed, wherein a spheroid cell culture was used to further purify viable CTCs after conventional negative selectionbased CTC isolation methods. Our results from a cancer cell line model revealed that the survival of leukocytes in spheroid cell cultures was significantly decreased with time, whereas OECM-1 cells maintained viability and proliferated. Therefore, such a cell culture operation was expected to increase cancer cell purity in the cell spheroids. This assumption was confirmed by our results, which showed that cancer cell purities were 10.6 to 80.3-fold increased after spheroid cell culture for 8 days. In the following clinical tests, CTC-related cells were observed in 6 of 13 blood samples. Furthermore, the average purity of CTC-related cells was 34.8 AE 14.0%. By utilizing a second-step spheroid cell culture operation, the purity of CTC-related cells was greatly improved when compared with that (less than 10%) achievable by conventional negative selection-based CTC isolation. Overall, this study proposed a twostep process for the isolation of high-purity, label-free, and viable CTCs.
Isolation of label-free and viable circulating tumour cells (CTCs) from blood samples of cancer patients through a two-step process: negative selectiontype immunomagnetic beads and spheroid cell culture-based cell isolation 
Introduction
Cancer metastasis is a leading cause of cancer-derived death.
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Circulating tumour cells (CTCs) are cells shed from primary tumours into adjacent vasculature and subsequently present in blood circulation. 2 Growing evidence has suggested that the existence of CTCs in blood circulation is associated with cancer metastasis or relapse. 1, 3, 4 Therefore, fundamental studies on CTCs have great potential for determining the mechanisms underlying cancer metastasis, which could facilitate the development of therapeutic solutions for cancer care. Moreover, several emerging studies have proposed that CTCs act as a realtime tumour biopsy to be utilized in the selection of therapeutic regimens for each unique cancer patient. 5 For this clinical utility, the responses of CTCs to anti-cancer drugs (e.g., through cell-based chemosensitivity assays) or CTC gene expression analyses can be used to guide personalized cancer chemotherapy and serve as a clinically important indicator for monitoring long-term therapeutic efficacy. 6 This can provide predictive information for the adjustment of therapeutic schemes throughout the stages of cancer care.
To achieve these goals, the isolation of high-purity, labelfree, viable, and clinically meaningful CTCs from blood samples of cancer patients is crucial. Recent progress in cell isolation techniques has allowed for the isolation of CTCs through various strategies, which can be broadly categorized into physical and biochemical-based schemes. 7 The isolation of CTCs in a blood sample based on physical differences (e.g., size 8 and density 9 ) between the CTCs and surrounding mononuclear cells is generally regarded as easy, label-free, and possible isolated viable cells but not as specic as biochemical-based methods.
10,11
Biochemical techniques commonly utilize magnetic beads (e.g., the FDA-approved CellSearch system 12 ) or specic surfaces (e.g., Isoux, 13 CTC chip, 5, 14 and MagSweeper 15 ) coupled with CTC surface antigen-specic antibodies to recognize and selective capture of CTCs. In these CTC isolation schemes, the targeted surface antigens on CTCs are either tumour-specic markers or epithelial-specic markers. For the latter, the most common used biomarkers are epithelial cell adhesion molecule (EpCAM) and cytokeratins (CKs). 16 These two surface antigens are expressed by cancer cells of epithelial origin and are normally absent in normal blood cells. The magnetic beads or surface-bound CTCs are then separated from the leukocyte background by a magnetic eld or buffer solution ow. CTC isolations based on this strategy are usually referred to as positive selections of CTCs and are considered mainstream methods in CTC isolation.
Although the positive selection-based CTC isolation schemes have been widely shown to be effective in isolating CTCs with high cell purities (e.g., enrichment factor of CellSearch system and CTC chip are 4.0 Â 10 4 , and 7.1 Â 10 4 , respectively [17] [18] [19] ), a few important biological issues should be addressed. First, EpCAM and CKs are not expressed in all tumours;
20 thus, such cell isolation strategies may not be suitable for some types of CTCs. Second, CTCs, particularly those with metastatic natures, may undergo the so-called epithelial-to-mesenchymal transition (EMT). 21 These CTCs subsequently reduce the expressions of EpCAM and CKs. 20 This phenomenon could prevent positive selection-based CTC isolation schemes from isolating clinically meaningful CTCs associated with cancer metastases. Moreover, CTCs harvested via these methods are typically labeled with magnetic beads or immobilized on a surface. This could greatly hamper their applications for subsequent cell-based assays (e.g., CTCs-based chemosensitivity assays). To address these issues, a few recent studies have proposed negative selectionbased strategies for CTC isolation, wherein only blood cells are targeted for depletion using standard immunomagnetic beads-based cell isolation methods. [22] [23] [24] This would leave all possible and label-free CTCs in the remaining cells. For example, Balasubramanian P. et al. utilized a negative selection strategy for CTC purication from head and neck cancer patients and demonstrated that putative CTCs are multitudinous phenotypes, both biological and physical. They identied putative CTCs, negative for EpCAM but positive for CK, epidermal growth factor receptor (EGFR), vimentin, CD44, from patients. 24 The negative selection methods are no prone to selection bias as positive selection strategies. However, most of these CTC isolation methods suffer from low CTC purity (e.g., enrichment factor of density gradient separation is 4.5 Â 10 2 ), 18,25 which could hinder the subsequent utilization of CTCs for specic applications (e.g., gene expression analyses
26
). To address these technical hurdles in positive or negative selection-based CTC isolation methods, this study proposed the combination of a three-dimensional (3-D) cell culture technique and a negative selection-based CTC isolation method. With recent advances in cell culture techniques, there is growing evidence that 3-D cell culture models provide more physiologically meaningful and biomimetic culture conditions for cultured cells in comparison with conventional 2-D monolayer cell culture models. 27 In general, 3-D cell cultures cultivate cells within 3-D scaffolding biomaterials or in cell aggregate spheroids. 28 based cell cultures). In our preliminary tests it was found that human leukocytes gradually die out in 3-D cell cultures within a few days. Based on these ndings, a two-step CTC isolation process was proposed, wherein a 3-D cell culture was utilized to further purify CTCs aer a negative selection-based CTC isolation process. One of the technical advantages of this hybrid cell isolation protocol is its ability to isolate label-free, high-purity and, most importantly, all possible CTCs in a blood sample without encountering issues related to the complexity of surface antigens on CTCs, as has been experienced by conventional positive selection-based CTC isolation methods. 20 Furthermore, recent reports have indicated that most CTCs in vivo die out soon aer entering blood circulation, leaving few viable CTCs. These physiologically unique, viable CTCs may be associated with subsequent cancer metastases. 31 Recently, a magnetic negative depletion following by the EPISPOT assay was proposed to detect viable CTCs. 32 Ramirez J. M. et al. demonstrated that concentrations of viable CTC (secretion of EpCAM and/or CK19 proteins) serve as an independent prognostic factor for metastatic breast cancer. 33 Thus, another key advantageous feature of the proposed two-step CTC isolation protocol is its ability to harvest viable CTCs with physiological and clinically meaningful characteristics.
In this study, we quantied the main cell populations (i.e., erythrocytes, CD45 pos leukocytes, and CD45 neg peripheral blood mononuclear cells (PBMCs), which may contain all possible CTCs) in blood samples, of healthy donors and head-and-neck cancer patients aer conventional negative selection-based CTC isolation methods. We further tested the feasibility of using 3-D cell culture models for CTC isolation and purication aer the negative selection-based CTC isolation processes. In the feasibility tests, we evaluated the survival of leukocytes isolated from the blood samples of healthy donors and cancer patients and the survival of OECM-1 cells (a cancer cell line model) in 3-D cell culture models (e.g., agarose hydrogel and spheroid-based cell cultures). Based on these experiments, the performance of the proposed two-step CTC isolation process was evaluated. Furthermore, the utilization of such a cell isolation process for the isolation of CTCs from the blood samples of head-and-neck cancer patients was demonstrated. Our results revealed that the major cell population in cell samples subjected to negative selection-based CTC isolation was CD45 pos leucocytes (85. 
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) obtained through a conventional negative selection-based CTC isolation process. Overall, this study proposed a twostep process for the isolation of high-purity, label-free and viable CTCs. Advanced head-and-neck cancer patients with histopathologically conrmed squamous cell carcinoma and healthy blood donors were enrolled in a single medical centre, the Chang Gung Memorial Hospital in Linkou, Taoyuan, Taiwan. All methods were carried out in accordance with relevant guidelines. Briey, peripheral blood samples (8 ml each) were obtained from healthy blood donors (n ¼ 6), and head-and-neck cancer patients (n ¼ 4). The samples were kept at 4 C and processed within 24 h. PBMCs were rst isolated from a whole blood sample using a commonly used density gradientbased separation method (Ficoll-Paque Premium, 1.077 g ml À1 ;
Materials and methods
GE Healthcare, Piscataway, NJ). 34 In the subsequent negative selection-based CTC isolation, CD45 magnetic beads (EasySep Human CD45 Depletion Kit; StemCell Technologies, Vancouver, BC, Canada) were used to deplete leukocytes from PBMCs per manufacturer instructions. The leukocyte depletion rate was evaluated by counting the numbers of PBMCs before and aer depletion treatment and calculated using the following equa-
Aer leukocyte depletion, the ratio of the erythrocytes, the CD45 pos leukocytes, and the CD45 neg PBMCs in the remaining cell sample were quantied microscopically with the aid of immunouorescent staining as previously described. Feasibility evaluation of using 3-D cell culture for further CTC isolation and purication aer negative selection-based CTC isolation process: cell line model A two-step process was proposed for CTC isolation, wherein a 3-D cell culture model was utilized to further purify CTCs aer a negative selection-based CTC isolation. The process was based on our initial hypothesis that leukocytes may gradually die in a 3-D cell culture model, whereas CTCs would survive. To test this hypothesis, experiments were carried out. The survival of leukocytes and OECM-1 cells (an oral cavity cancer cell line model) in the 3-D cell culture models (i.e., agarose hydrogel and spheroid-based cell cultures) were evaluated. Briey, the PBMCs were rst isolated from the blood samples of healthy donors and head-and-neck cancer patients as described earlier. The agarose hydrogel-based 3-D cell cultures were carried out using a CytoSelect Clonogenic Tumour Cell Isolation Kit (Cell Biolabs, Inc., San Diego, CA), and prepared per manufacturer instructions. Briey, the wells of a 96-well microplate were coated with base agar matrix and incubated at 4 C for 30 min for gelation.
PBMC (2 Â 10 4 cells per well), and OECM-1 (1 Â 10 3 cells per well) cell suspensions were prepared and individually mixed with the pre-melted agar matrix. Subsequently, these mixes were loaded onto the base agar matrix layer of each well. Aer 20 min of incubation at 4 C, 100 ml of CTC culture medium (RPMI1640 medium (Gibco Invitrogen, Carlsbad, CA) supplemented with epidermal growth factor (EGF, 10 ng ml À1 ; Gibco Invitrogen), basic broblast growth factor (bFGF, 10 ng ml À1 ;
Gibco Invitrogen) and B-27 supplements (Gibco Invitrogen)) was added to each well. The spheroid-based cell culture model was performed based on a previously described method. were prepared in CTC culture medium and seeded in the wells of a 48-well microplate pre-coated with 2% agarose. In addition to the aforementioned cell culture preparations, OECM-1 cells (5.0%) were also co-cultured with PBMCs in the two 3-D cell culture models as described earlier.
To determine the cancer cell purity before and aer the spheroid-based cell culture, the OECM-1 cells capable of stably expressing green uorescence protein (GFP), referred to as OECM-1-GFP cells, were spiked into PBMCs (2 Â 10 4 cells) at 5.0%, 1.0%, and 0.2% and cultured in the spheroid-based cell culture model. Culture media were replaced every 3 days. PMBC survival in the two 3-D cell culture models was assayed using trypan blue staining and microscopic observations 37 at days 0, 4, 8, and 12. The data is presented as survival ratio [(the number of live cells at a particular time point/the number of live cells at day 0) Â 100%]. For the OECM-1 cells, the commonly used methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay 38 was used to quantify viable OECM-1 cells at days 0, 2, 4, and 8. Additionally, to determine cell viability, cells were stained with calcein AM viability dye (1 : 1000 dilution, Invitrogen, Carlsbad, CA) and Hoechst 33342 (5 mg ml À1 , Molecular
Probes, Carlsbad, CA) and subsequently observed by uores-cence microscopy. For the OECM-1-GFP and PBMC co-cultures in the spheroid-based cell culture model, uorescent images of OECM-1-GFP cells were observed at days 0 and 8. Cells at days 0, 4, and 8 were harvested and stained with DRAQ5 nuclear dye (5 mM; eBioscience, San Diego, CA) and assayed cancer cell purity by ow cytometry. Cancer cell purity (%) was calculated: (number of GFP pos cells/number of all nucleated cells) Â 100%.
Demonstration of using the two-step cell isolation process for CTC isolation: clinical sample tests
To demonstrate the feasibility of using the proposed two-step cell isolation for CTC isolation, the following clinical tests were carried out. Blood samples (8 ml each; n ¼ 13) were obtained from patients diagnosed with head-and-neck cancer.
PBMCs were isolated and subjected to a negative selectionbased CTC isolation as described earlier. Aer these, a quarter of each cell sample was analysed to quantify the EpCAM pos CTC number based on a previously described method. 34 Each remaining sample was cultured in a spheroid-based cell culture model as described earlier. Aer 8 days of culture, cells in the cell spheroid were stained with calcein AM viability dye and other immunouorescent dyes to label viable CTC-related cells observed by uorescence microscopy. For immunouorescent assays, the cultured cells were pre-treated according to previously described methods. 35 Cell samples were incubated in primary antibodies for 2 h at room temperature. Aer washing with PBST (0.05% Triton X-100 in PBS) twice, the cells were incubated in secondary antibodies and Hoechst 33342 dye for 30 min at room temperature. Fluorescent images were then acquired using a uorescent microscope. The antibodies used were anti-CD45-PE conjugated antibody (1 : 100 dilution; clone 5B1, Miltenyi Biotec, GmbH, Germany), anti-wide spectrum cytokeratin antibody (1 : 100 dilution; Abcam, Inc., Cambridge, MA), anti-vimentin antibody (1 : 500 dilution; GeneTex, San Antonio, TX), Alexa Fluor 488 conjugated goat anti-rabbit secondary antibody (1 : 500 dilution; Thermo Fisher Scientic), and Alexa Fluor 594 conjugated donkey anti-mouse secondary antibody (1 : 500 dilution; Thermo Fisher Scientic 20 To address this issue, a two-step, label-free, highpurity, and physiologically meaningful CTC isolation process was presented in this study. A density-gradient separation and negative selection-type immunomagnetic beads-based method was carried out in a rst step, followed by CTC purication using a 3-D cell culture technique. In this study, the capture efficiency of OECM-1 cells was evaluated by performing a cancer cell spiking test. Results showed that around 53% and 84% of the spiked OECM-1 cells were recovered by the density-gradient separation and negative depletion processes, respectively. These performances were comparable with previously reported. 34, 40 We quantied the differences in the main cell populations in blood samples of healthy donors and head-and-neck cancer patients aer negative selection-based CTC isolation. PBMCs were isolated from whole blood samples (average PBMCs per ml blood: 1.4 AE 0.6 Â 10 6 cells per ml; n ¼ 10). In the subsequent immunomagnetic beads-based CTC isolation, the average leukocyte depletion rate was found to be 98.8 AE 0.9%, indicating that most of the leukocytes in a treated sample were removed. The remaining cell populations in the cell samples were quantied via microscopy ( Fig. 1A ) and ow cytometry ( Fig. 1B and C) . The results (Fig. 1A) ), were detected in all blood samples (Fig. 1A) . More importantly, the CD45 neg PBMCs were more prevalent in the blood samples of cancer patients than in those of healthy donors (the average percentage for healthy blood donors and cancer patients were 1.9 AE 1.4% and 4.5 AE 2.7%, respectively; mean AE S.D., P ¼ 0.27, Mann-Whitney U test). Consistent results were also reported via ow cytometry (Fig. 1B and C). These results (Fig. 1C) 45 This implied that more than half of advanced head-and-neck cancer cases were not properly diagnosed by conventional positive selection strategies. Taken together, the key technical advantage of exploiting a negative selection strategy for CTC isolation is its ability to harvest EpCAM neg /CD45 neg cancer cells, which are generally ignored by positive selection. However, the majority of cell species (85.4 AE 2.4% for cancer patient cases) in cell samples obtained aer negative selection-based CTC isolations was CD45 pos leukocytes (Fig. 1A) even through 98.8% of the original leukocyte population were removed by negative selection. The low CTC purity is a major shortcoming of negative selection-based CTC isolation methods. 25 Such a low CTC purity may cause problems when harvested CTCs are used for subsequent analyses (e.g., gene expression analyses 26 ). To address this issue, a 3-D cell culture technique was proposed to further purify CTCs.
Use of 3-D cell culture for further CTC isolation and purication aer negative selection-based CTC isolation process: feasibility evaluation based on cell line model
There are approximately 3-4 Â 10 6 CTCs in blood circulation per one gram of tumour tissue. 46 However, only 0.01% of CTCs survive and are capable of forming micro-metastases in distant tissues. 31 Thus, only small cell populations within CTCs are considered responsible for cancer metastases. 31 Analyses of these biologically and clinically meaningful CTCs would likely provide useful information on mechanisms underlying cancer metastases or on suitable therapeutic drugs. 47 To achieve this goal, the isolation of CTCs in a high-purity and a biologically meaningful manner is crucial. However, this is not achievable using conventional positive or negative selection-based cell isolation schemes.
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To address this issue, we utilized a 3-D cell culture method to further improve the cell purity of isolated CTCs and to selectively harvest viable CTCs aer a negative selection-based CTC isolation process. Recent progress in cell culture techniques, especially the culture of CTCs from blood samples of breast, 6 prostate, 30 colon, 48 and lung 49 cancer patients, has been successfully demonstrated. In these studies, spheroid cell culture models (i.e., a 3-D cell aggregate culture) were used due to a number of advantages. First, sphere formation is a biological feature of stem cells. 50 A few types of cancer cells have been recognized to possess characteristic properties of stem cells; these cells are oen referred to as cancer stem cells. With similar stem cell properties, CTCs could more effectively survive the challenges of blood circulation and establish cancer metastases. [51] [52] [53] [54] Second, a recent report disclosed that CTC neg PBMCs. The quantification results (the CD45 neg cells per ml blood) were shown in panel (C) and the statistic differences between groups were compared using Mann-Whitney U test.
clusters (i.e., CTC aggregates) provide survival advantages in the bloodstream 55 and thus have higher metastatic ability than single CTCs. 56 These advantages of utilizing a spheroid cell culture model for CTC culture would likely preserve viable CTCs.
In this work, we assumed that CTCs in cell samples obtained aer negative selection-based CTC isolation survived spheroidal cell culture, whereas leukocytes, which comprise the major cell population (Fig. 1A) , gradually die in such cell culture conditions. Leukocytes are naturally mobile cells in blood circulation and thus, would unlikely adapt to a cell aggregate-based culture format. In addition to a spheroid cell culture model, we also explored the suitability of using a 3-D hydrogel-based cell culture, wherein cultured cells are encapsulated within a 3-D hydrogel matrix. Results ( Fig. 2A) revealed that the survival ratio of leukocytes from healthy blood donors and cancer patients in the two 3-D cell culture models signicantly decreased with culture time. For the 3-D hydrogel-based cell culture, the survival ratio of leukocytes from healthy blood donors and cancer patients at days 8 and 12 were 16.5 AE 6.0% and 7.2 AE 1.7%, and 19.7 AE 5.6% and 12.1 AE 1.4%, respectively. Regarding the spheroid cell culture, the survival ratio were 24.5 AE 3.1% and 15.3 AE 6.4%, and 23.6 AE 1.2% and 18.7 AE 1.7%. No signicant differences were observed among the survival ratios of leukocytes at each time point tested (Fig. 2A) . These results indicated that the origin of leukocytes and the different 3-D cell culture models did not affect leukocyte cell viability within the investigated conditions. OECM-1 cultures were also examined using two 3-D culture models. A conventional 2-D monolayer cell culture model was also prepared for comparison. As expected, OECM-1 cells maintained viability and signicantly proliferated in the monolayer model (Fig. 2B) . Conversely, while the OECM-1 cultures in the 3-D hydrogel-based cell culture maintained viability (survival ratio: 133.3-166.7%), they proliferated less signicantly when compared with the cultures in the monolayer model. These outcomes were consistent with previous ndings showing that cells cultured in monolayers proliferated more rapidly than those in 3-D environments. 57 For the spheroid cell culture model (Fig. 2B) , the OECM-1 cells maintained viability (survival ratio: 172.2-338.9%) and proliferated more signi-cantly than those in the 3-D hydrogel-based culture, particularly aer day 4. Fig. 2C shows light microscopy images of cells (i.e., PBMCs, OECM-1 cells, and their co-culture) cultured in the three cell culture models. The PBMCs did not adhere on 2-D surfaces ( Fig. 2C(a) ) or form cell spheroids in the two 3-D cell cultures (Fig. 2C(b) and (c)) aer 7 days of culture. This could be attributed to their inherent non-anchoring nature. For the OECM-1 cells, they adhered and spread on 2-D surfaces (Fig. 2C(d) ) as expected, maintained spherical morphologies in the 3-D hydrogel-based culture (Fig. 2C(e) ), and formed spheroids in the spheroid culture model (Fig. 2C(f) ). In the cocultures of PBMCs and OECM-1 cells, the results (Fig. 2C(g)-(i) ) showed that the existence of PBMCs in a cell sample did not affect the formation of cancer cell spheroids (Fig. 2C(i) ). However, the results described above were based on a cancer cell line model. Reverse result was reported in previous publication 58 showing that primary cancer cells proliferated less in a 2-D monolayer cell culture model than they in a 3-D cell culture model. As discussed earlier, 3-D spheroid culture model was more commonly adopted for CTC culture in recent publications. 6, 48 Taken together, the spheroid cell culture model was selected for CTC isolation in this study.
To determine the cell viability of the cultures in the spheroid cell culture model, cell samples were stained with uorescent dyes and observed microscopically. The results (Fig. 2D(a) ) showed that most of the PBMCs in the spheroid cell culture models were dead (calcein neg /Hoechst pos ) aer 7 days of culture, which correlated with the results shown in Fig. 2A . Additionally, the OECM-1 cells cultured in the spheroid model maintained high cell viability as seen in Fig. 2D (b) (calcein pos /Hoechst pos ).
In the co-culture microscopy images (Fig. 2D(c) ) revealed that cancer cell aggregates had formed, and high cell viability was maintained. To evaluate the performance of the proposed spheroid-based cell culture for improving the CTC purity, OECM-1-GFP cells were spiked into PBMCs at the 5.0%, 1.0% and 0.2%, to mimic the CTC purity range normally achieved by conventional negative selection-based CTC isolation. 25 Aer 8 days of co-culture of OECM-1-GFP cells and PBMCs, uorescent images of the cell aggregate spheroids were obtained. The results (Fig. 2E) showed that the pure OECM-1-GFP cells formed cell aggregate spheroids at day 1 ( Fig. 2E(a) and (b) ). The spheroid slightly expanded due to cell growth by day 8 (Fig. 2E(c) and (d) ). Similar results were also observed for the cell samples containing 1.0% and 5.0% OECM-1-GFP cells (Fig. 2E(e) to (l) ). Based on the proliferation of cancer cells ( Fig. 2B and E ) and the death of leukocytes ( Fig. 2A ) in cell spheroids, such a cell culture operation was expected to increase cancer cell purity in the spheroid sample. To quantitatively analyse cancer cell purity, cell aggregate spheroids formed at days 0, 4, and 8 were harvested and assayed using ow cytometry. The results (Table 1) showed that cancer cell purities were 4.2-10.3 and 10.6-80.3-fold higher aer spheroid cell culture for 4 and 8 days, respectively. Therefore, an 8 day spheroid cell culture was used for clinical tests to improve cancer cell purity to 49.6%, 29.5%, and 6.4% from original cancer cell purities of 4.7%, 1.1%, and 0.08%, respectively ( Table 1) .
Demonstration of the two-step cell isolation process for CTC isolation: clinical tests
The spheroid cell culture model was selected for CTC isolation based on the results shown in Fig. 2A-E . In the following clinical tests, 13 blood samples obtained from patients diagnosed with head-and-neck cancer were rst subjected to negative selection-based CTC isolation processes followed by EpCAM pos cell enumeration using a published protocol.
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Finally, the treated cell samples were cultured in the spheroid culture model. Immunouorescent staining and uorescent microscopy were used to determine whether a cell spheroid sample contained CTC-related cells. determine the suitability of using the proposed two-step process for CTC isolation. In this study, EpCAM pos CTCs were detected in all tested samples (except for no. 5 sample, we failed to acquire the enumeration data). However, CTC-related cells were only observed in 6 of 13 cell culture samples ( Table 2 ). The phenomenon could be explained by the fact that most CTCs could die soon aer entering into bloodstream and only a small portion of them could survive in such condition. 31 This could again point out the key advantage of utilizing an additional in vitro cell culture operation is its ability to further purify the live The consistent results were also demonstrated in this study. Nevertheless, some different ndings were also found in these two studies. First, aer 8 days of spheroid cell culture, some 
Conclusion
In this study, we proposed a two-step CTC isolation and purication scheme. A 3-D cell culture model was used to further purify viable, label-free, and high purity CTCs aer conventional negative selection-based isolation process. Our results revealed that the majority cell species in cell sample obtained aer negative selection was CD45 pos leukocytes (85.4-90.7%) even though 98.8% of the original leukocytes were removed by negative depletion processes. Therefore, strategies to further purify CTC are required. Additionally, our results showed that the CD45 neg PBMCs were more prevalent in the blood samples of cancer patients than in those of healthy donors. These results highlight the key technical advantage of exploiting a negative selection strategy for CTC isolation is its ability to harvest EpCAM neg /CD45 neg CTCs, which are generally ignored by positive selection. Based on the proliferation of cancer cells and the death of leukocytes in cell spheroids, we proposed to utilize the spheroid-based cell culture to increase cancer cell purity in the cell sample aer negative selection. Our results demonstrated that such a cell culture operation could improve the purities of cancer cell by 10.6 to 80.3-fold aer 8 days of culture. In the following clinical tests, cultivable CTC-related cells were observed in approximately half of samples (6/13) aer 8 days of culture. The average purity of CTC-related cells was 34.8 AE 14.0%, which was greatly improved when compared with those achievable by conventional negative selection-based CTC isolation methods. Overall, this study proposed a two-step process, negative selection-based CTC isolation followed by 3-D spheroid culture, for the isolation of high-purity, label-free, and viable CTCs.
